Document and Entity Information - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2024 |
May 06, 2024 |
|
| Cover [Abstract] | ||
| Document Type | 10-Q/A | |
| Amendment Flag | true | |
| Amendment Description | Phathom Pharmaceuticals, Inc., or the Company, is filing this Amendment No. 1, or the Amendment, on Form 10-Q/A to amend its original Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, or the Original Form 10-Q, originally filed with the Securities and Exchange Commission, or SEC, on May 9, 2024, for the sole purpose of filing revised Exhibits 31.1 and 31.2 in order to include in the certifications set forth in such exhibits the language of revised paragraph 4(b), which language was inadvertently omitted from the certifications when originally filed as Exhibits 31.1 and 31.2. This Amendment consists solely of the preceding cover page, this explanatory note, Item 1, the list of exhibits filed with this Amendment, the signature page and the revised certifications filed as Exhibits 31.1 and 31.2 to this Amendment and the required certifications required by the Sarbanes-Oxley Act in connection with the filing of this Amendment. Except as described above, this Amendment does not reflect events occurring after the date of the filing of the Original Form 10-Q or modify or update any of the other disclosures contained therein in any way. Accordingly, this Amendment should be read in conjunction with the Original Form 10-Q and the Company’s other filings with the SEC. This Amendment does not reflect events that may have occurred subsequent to the filing of the Original Form 10-Q. The filing of this Amendment is not an admission that the Original Form 10-Q, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading. | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Entity Interactive Data Current | Yes | |
| Document Period End Date | Mar. 31, 2024 | |
| Document Fiscal Year Focus | 2024 | |
| Current Fiscal Year End Date | --12-31 | |
| Document Fiscal Period Focus | Q1 | |
| Entity Registrant Name | PHATHOM PHARMACEUTICALS, INC. | |
| Entity Central Index Key | 0001783183 | |
| Entity Tax Identification Number | 82-4151574 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity File Number | 001-39094 | |
| Entity Shell Company | false | |
| Entity Emerging Growth Company | true | |
| Entity Ex Transition Period | true | |
| Entity Small Business | true | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 100 Campus Drive | |
| Entity Address, Address Line Two | Suite 102 | |
| Entity Address, City or Town | Florham Park | |
| Entity Address, State or Province | NJ | |
| Entity Address, Postal Zip Code | 07932 | |
| City Area Code | 877 | |
| Local Phone Number | 742-8466 | |
| Entity Common Stock, Shares Outstanding | 58,535,193 | |
| Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
| Trading Symbol | PHAT | |
| Security Exchange Name | NASDAQ |